October 22, 2022
Altamira Therapeutics Announces Divestiture of Inner Ear Development Assets
HAMILTON, BERMUDA , Oct. 21, 2022 (GLOBE NEWSWIRE) — Definitive agreement to sell 90% stake in Company’s Zilentin subsidiary with…
Pharmaceuticals, Biotechnology and Life Sciences
HAMILTON, BERMUDA , Oct. 21, 2022 (GLOBE NEWSWIRE) — Definitive agreement to sell 90% stake in Company’s Zilentin subsidiary with…
Data collected shows importance of treatment formulation characteristics and speed of improvement in psoriasis symptoms to patient treatment adherenceDURHAM, N.C.…
Research shows PAD (Polyaphron Dispersion) Technology™ leads to more efficient delivery of Calcipotriene (CAL) and Betamethasone Dipropionate (BDP) than CAL/BDP topical…
WALTHAM, Mass., Oct. 21, 2022 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (NASDAQ: CINC) today announced the publication of Phase 1…
NEW YORK, Oct. 21, 2022 (GLOBE NEWSWIRE) — Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet®…
DURHAM, N.C., Oct. 21, 2022 (GLOBE NEWSWIRE) — NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company focused on developing…
Findings presented at the annual Fall Clinical Dermatology ConferenceSurvey found that path to diagnosis for people with seborrheic dermatitis (average…
Study Design EnACT Phase 2 Design Two-week survival in Cohort 4 (all-oral regimen) was 95% in 40 patients receiving MAT2203 …
– Two preclinical posters highlighting the JTX-1484 program and LILRB family at SITC 2022 – – Two clinical posters highlighting…
Ridinilazole resulted in a 53% relative risk reduction in recurrence of C. difficile infection compared to treatment with vancomycin Ridinilazole…